<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" open-status="O" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Dement Geriatr Cogn Dis Extra</journal-id><journal-id journal-id-type="iso-abbrev">Dement Geriatr Cogn Dis Extra</journal-id><journal-id journal-id-type="publisher-id">DEE</journal-id><journal-title-group><journal-title>Dementia and Geriatric Cognitive Disorders EXTRA</journal-title></journal-title-group><issn pub-type="ppub">1664-5464</issn><issn pub-type="epub">1664-5464</issn><publisher><publisher-name>S. Karger AG</publisher-name><publisher-loc>Allschwilerstrasse 10, P.O. Box · Postfach · Case postale, CH–4009, Basel, Switzerland · Schweiz · Suisse, Phone: +41 61 306 11 11, Fax: +41 61 306 12 34, karger@karger.ch</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">3808222</article-id><article-id pub-id-type="doi">10.1159/000354369</article-id><article-id pub-id-type="publisher-id">dee-0003-0272</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research Article</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="15475" pm="."><plain>Genetic Association between Neurotrophin-3 Polymorphisms and Alzheimer's Disease in Japanese Patients </article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Nagata</surname><given-names>Tomoyuki</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref ref-type="aff" rid="aff2"><sup>b</sup></xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Shibata</surname><given-names>Nobuto</given-names></name><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Shinagawa</surname><given-names>Shunichiro</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Nakayama</surname><given-names>Ritsuko</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kuerban</surname><given-names>Bolati</given-names></name><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ohnuma</surname><given-names>Tohru</given-names></name><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Arai</surname><given-names>Heii</given-names></name><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Nakayama</surname><given-names>Kazuhiko</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yamada</surname><given-names>Hisashi</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib></contrib-group><aff id="aff1"><sup>a</sup>Department of Psychiatry, Institute of DNA Medicine, Jikei University School of Medicine, Tokyo, Japan</aff><aff id="aff2"><sup>b</sup>Division of Molecular Genetics, Institute of DNA Medicine, Jikei University School of Medicine, Tokyo, Japan</aff><aff id="aff3"><sup>c</sup>Department of Psychiatry, Juntendo University School of Medicine, Tokyo, Japan</aff><author-notes><corresp id="cor1">*Tomoyuki Nagata, Division of Molecular Genetics, Institute of DNA Medicine, Jikei University School of Medicine, 3-25-8 Nishishimbashi, Minato-ku, Tokyo 105-8471 (Japan), E-Mail <email>t.nagata@jikei.ac.jp</email></corresp></author-notes><pub-date pub-type="collection"><season>Jan-Dec</season><year>2013</year></pub-date><pub-date pub-type="epub"><day>7</day><month>9</month><year>2013</year></pub-date><pub-date pub-type="pmc-release"><day>7</day><month>9</month><year>2013</year></pub-date><volume>3</volume><issue>1</issue><fpage>272</fpage><lpage>280</lpage><permissions><copyright-statement>Copyright © 2013 by S. Karger AG, Basel</copyright-statement><copyright-year>2013</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions.</license-p></license></permissions><abstract><sec><title><text><SENT sid="15476" pm="."><plain>Background </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="15477" pm="."><plain>Some polymorphisms of the neurotrophin family have previously been investigated as candidate genes for Alzheimer's disease (AD). </plain></SENT>
<SENT sid="15478" pm="."><plain>In the present study, we examined whether neurotrophin-3 (NTF-3) polymorphisms are genetic risk factors in patients with AD. </p></sec><sec><title><text><SENT sid="15479" pm="."><plain>Methods </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="15480" pm="."><plain>From a sample of 507 subjects, we recruited 248 age-matched subjects divided into 2 groups: AD patients (n = 143) and normal controls (NCs) (n = 105). </plain></SENT>
<SENT sid="15481" pm="."><plain>We identified 3 representative NTF-3 single nucleotide polymorphisms (SNPs): rs6332, rs6489630, and rs4930767. </plain></SENT>
<SENT sid="15482" pm="."><plain>Next, we statistically compared the allele frequencies of each SNP between the AD and NC groups in the early-onset (&lt;65 years) cases under a more limited age-matched condition. </p></sec><sec><title><text><SENT sid="15483" pm="."><plain>Results </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="15484" pm="."><plain>We found a significant association between rs6332 and the total group of AD patients (p = 0.013) and significant associations between both rs6332 (p = 0.033) and rs6489630 (p = 0.035) and early-onset AD patients. </p></sec><sec><title><text><SENT sid="15485" pm="."><plain>Conclusion </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="15486" pm="."><plain>These results suggest that NTF-3 SNPs may not only be associated with AD itself, but also with early-onset AD in Japanese patients, assuming that the NTF-3 gene may have age-related effects on neurodegenerative diseases. </p></sec></abstract><SecTag type="KEYWORD"><kwd-group><title>Key Words </title><kwd>Neurotrophin-3</kwd><kwd>Single nucleotide polymorphisms</kwd><kwd>Alzheimer's disease</kwd><kwd>Neurotrophins</kwd><kwd>Polymorphism </kwd></kwd-group></SecTag><counts><table-count count="4"/><ref-count count="34"/><page-count count="9"/></counts></article-meta></front><body><SecTag type="INTRO"><sec id="sec1_1"><title><text><SENT sid="15487" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="15488" pm="."><plain>Alzheimer's disease (AD) has a progressive neurodegenerative course characterized mainly by memory disorder, visuospatial impairment, and executive dysfunction as its core symptoms [1,2]. </plain></SENT>
<SENT sid="15489" pm="."><plain>The deposition of causative proteins, such as amyloid-beta (Aβ) and tau, in the pathogenesis of AD has previously been reported and has been focused on as a possible therapeutic target [4,5]. APOE has been considered as a strong candidate gene for sporadic AD since the 1990s, and this speculation has recently been verified in a large-sample genome-wide association study [6,7]. </plain></SENT>
<SENT sid="15490" pm="."><plain>In Japan, a significant association between APOE and late-onset AD was replicated in a recent large-scale study [8]. </plain></SENT>
<SENT sid="15491" pm="."><plain>On the other hand, various lifestyle-related diseases have been reported as risk factors, and sporadic AD itself is considered to be caused by a combination of several genetic and environmental factors [9,10]. <p><text><SENT sid="15492" pm="."><plain>In postmortem analyses of the brain of patients with AD, regional quantitative alterations in neurotrophins, such as nerve growth factor, brain-derived neurotrophic factor (BDNF), and neurotrophin-3 (NTF-3), have been reported [11,12,13]. </plain></SENT>
<SENT sid="15493" pm="."><plain>Similar results were obtained in AD mouse models, and these neurotrophins have been considered as practical therapeutic targets in AD patients or rodents [14,15,16]. </plain></SENT>
<SENT sid="15494" pm="."><plain>Among such representative neurotrophins, NTF-3, in particular, protects cortical neurons against Aβ-dependent neural cell death by limiting caspase-8, caspase-9, and caspase-3 cleavage [17]. </plain></SENT>
<SENT sid="15495" pm="."><plain>On the other hand, NTF-3 influences the development of mesolimbic dopaminergic neurons and the differentiation of noradrenergic neurons in the locus ceruleus [18,19]. <p><text><SENT sid="15496" pm="."><plain>While some previous studies had reported BDNF polymorphisms to be risk factors for AD in Japanese populations, we observed that some single nucleotide polymorphisms (SNPs) of neurotrophins are associated with cognitive impairment in patients with AD [20,21,22,23,24,25]. </plain></SENT>
<SENT sid="15497" pm="."><plain>Among the candidate genes in the neurotrophin family, Kunugi et al. [23] found that a missense mutation (Gly/-63/Glu) in the NTF-3 gene was associated with a risk of AD; however, its mutant type (-63 Glu) was too rare in Caucasian populations to be investigated in subsequent studies in other countries [23,26]. </plain></SENT>
<SENT sid="15498" pm="."><plain>On the other hand, NTF-3 has been reported to be a strong candidate gene for attention deficit/hyperactivity disorder (ADHD), in which social cognition is impaired as a core symptom in the neurodevelopmental course [27]. NTF-3 SNPs (rs6332 and rs6489630) are functional polymorphisms located at chromosome 12p13 and are significantly associated with the severity of ADHD and intelligence (i.e. selective attentional tasks and performance execution) [28,29]. </plain></SENT>
<SENT sid="15499" pm="."><plain>A silent polymorphism, rs6332, is located within Pro-NTF-3 gene exon 1 and influences the executive function in patients with limited mild-stage AD, but not mild cognitive impairment (MCI) [20]. </plain></SENT>
<SENT sid="15500" pm="."><plain>The rs4930767 polymorphism in the promoter region of the same gene does not appear to be associated with any measure of ADHD [29]. </plain></SENT>
<SENT sid="15501" pm="."><plain>Based on these studies, the neurodevelopmental or neurodegenerative associated gene, NTF-3, may influence the age-related effects during the course of the disease, and such confounding effects should be considered when comparing the disease group and the normal control (NC) group. <p><text><SENT sid="15502" pm="."><plain>In the present study, we hypothesized that representative NTF-3 SNPs (rs6332, rs6489630, and rs4930767) might be associated with a risk of AD in Japanese subjects, a topic that is of particular interest in view of Japan's aging society. Thus, to investigate the association between AD and NTF-3 SNPs without age as a confounding factor, we statistically compared the allele frequencies of 3 SNPs between AD patients and age-matched NCs. Moreover, to compare these 2 groups under stricter or more limited age-matched conditions, we selected only the early-onset sample (&lt;65 years) from the total sample (age range, 32-72 years) in the second stage of the analysis [9]. </sec></SecTag><SecTag type="METHODS"><sec sec-type="methods" id="sec1_2"><title><text><SENT sid="15505" pm="."><plain>Methods </plain></SENT>
</text></title><sec id="sec2_1"><title><text><SENT sid="15506" pm="."><plain>Participants </plain></SENT>
</text></title><p><text><SENT sid="15507" pm="."><plain>Of the 507 Japanese subjects enrolled in the present genomic study, including patients with AD (n = 340; age range, 35-92 years; mean ± SD, 72.41 ± 10.71 years), patients with MCI (n = 47; age range, 63-83 years; mean ± SD, 75.26 ± 4.56 years), and NCs (n = 120; age range, 32-81 years; mean ± SD, 61.86 ± 8.41 years), we excluded 47 patients with MCI and 212 subjects (AD: n = 197; NCs: n = 15) who were older than 73 years. Thus, an age-matched sample (age range, 32-72 years; mean ± SD, 61.20 ± 7.24 years) of 248 subjects (AD: n = 143; NCs: n = 105) was recruited. All subjects were outpatients who had visited a memory clinic at the Jikei University Hospital (Tokyo), the Jikei University Kashiwa Hospital (Kashiwa city, Chiba prefecture), or the Juntendo University Hospital (Tokyo). </plain></SENT>
<SENT sid="15510" pm="."><plain>They were all diagnosed with probable AD based on the National Institute of Neurology and Communicative Disorder and Stroke/Alzheimer Disease and Related Disorder Association (NINCDS/ADRDA) criteria or the diagnostic criteria for MCI [3,30,31]. </plain></SENT>
<SENT sid="15511" pm="."><plain>This study was approved by the Ethics Committee of the Jikei University School of Medicine (Tokyo and Kashiwa) and Juntendo University School of Medicine (Tokyo). </plain></SENT>
<SENT sid="15512" pm="."><plain>Written informed consent was obtained from both the patients and their caregivers. </sec><sec id="sec2_2"><title><text><SENT sid="15513" pm="."><plain>Identification of NTF-3 SNP Genotypes </plain></SENT>
</text></title><p><text><SENT sid="15514" pm="."><plain>The method used to identify the NTF-3 SNP (rs6332, rs6489630, rs4930767) genotypes, a SNaPshot analysis (Applied Biosystems, Foster City, Calif., USA), has been described in previous reports [20,21,32]. </plain></SENT>
<SENT sid="15515" pm="."><plain>If the genotype of the SNP was unclear or ambiguous when determined using the SNaPshot method, we rechecked and confirmed the genotype using PCR products and direct nucleotide sequencing using an ABI 3730 DNA Analyzer [sequencing reactions were performed using BigDye Terminator v3.1 Cycle Sequencing Kits (Applied Biosystems)]. </plain></SENT>
<SENT sid="15516" pm="."><plain>All sequence analyses were performed using DNA Sequencing Analysis software, version 5.3.1 (Applied Biosystems). </sec><sec id="sec2_3"><title><text><SENT sid="15517" pm="."><plain>Comparing Allele Frequencies of rs6332, rs6489630, and rs4930767 between the Total and Early-Onset Group of Patients and the NCs </plain></SENT>
</text></title><p><text><SENT sid="15518" pm="."><plain>We statistically compared the allele frequencies of the NTF-3 SNPs (rs6332, rs6489630, rs4930767) between all patients with AD (total) and the NCs. Next, to investigate the relation under a more limited age-matched condition, we analyzed 163 (AD: n = 86; NCs: n = 77) early-onset cases (&lt;65 years); the frequencies of each allele were the same between the AD patients and the NCs. </sec><sec id="sec2_4"><title><text><SENT sid="15520" pm="."><plain>Statistical Analysis </plain></SENT>
</text></title><p><text><SENT sid="15521" pm="."><plain>SPSS 19.0J for Windows (SPSS Japan Inc.) was used for all statistical analyses. To control for type I errors, we used a one-way ANOVA with a post hoc Tukey test for age. The sex ratio (female to male) and allele frequencies of the NTF-3 SNPs were assessed using the Fisher exact probability test; the odds ratio (OR) was then calculated. A χ2 test was used to compare the distributions among the 3 genotypic groups. To assess the deviation of SNPs from Hardy-Weinberg equilibrium (HWE), we used the HWE calculator Web program (<ext-link ext-link-type="uri" xlink:href="http://www.oege.org/software/hwe-mr-calc.shtml">http://www.oege.org/software/hwe-mr-calc.shtml</ext-link>). </plain></SENT>
<SENT sid="15526" pm="."><plain>Moreover, we performed power calculations using the G* Power 3 (<ext-link ext-link-type="uri" xlink:href="http://www.psycho.uni-duesseldorf.de/abteilungen/aap/gpower3/">http://www.psycho.uni-duesseldorf.de/abteilungen/aap/gpower3/</ext-link>). </plain></SENT>
<SENT sid="15527" pm="."><plain>A p value &lt;0.05 was considered statistically significant. </sec></sec></SecTag><SecTag type="RESULTS"><sec sec-type="results" id="sec1_3"><title><text><SENT sid="15528" pm="."><plain>Results </plain></SENT>
</text></title><sec id="sec2_5"><title><text><SENT sid="15529" pm="."><plain>Characteristics, Genotype Distributions, and Allele Frequencies of All Subjects </plain></SENT>
</text></title><p><text><SENT sid="15530" pm="."><plain>Among the 248 subjects that were selected, the age and sex ratios of the patients with AD (n = 143) were not significantly different from those of the NCs (n = 105) (tables 1, 2). </plain></SENT>
<SENT sid="15531" pm="."><plain>The genotype distributions of rs6332 (G/G: n = 71, G/A: n = 130, A/A: n = 45), rs6489630 (C/C: n = 141, C/T: n = 93, T/T: n = 11), and rs4930767 (T/T: n = 94, C/T: n = 112, C/C: n = 40) among the total patient group did not deviate significantly from the HWE (p &gt; 0.05) (tables 3, 4). </plain></SENT>
<SENT sid="15532" pm="."><plain>The results of power analyses demonstrated that the power ranged from 50.8% (rs6332) to 78.9% (rs4930767). </plain></SENT>
<SENT sid="15533" pm="."><plain>The genotypic distribution of rs6332 was significantly deviated (χ2 = 6.979, d.f. = 2, p = 0.031) and its allele frequency was significantly different between the patients with AD and the NCs (χ2 = 6.496, d.f. = 1, p = 0.013, OR = 1.602) (tables 3, 4). </plain></SENT>
<SENT sid="15534" pm="."><plain>However, we could not find any significant differences in the genotypic allele frequencies of rs6489630 (χ2 = 3.523, d.f. = 1, p = 0.067, OR = 0.670) or rs4930767 (χ2 = 0.133, d.f. = 1, p = 0.779, OR = 1.071) between the patients with AD and the NCs (tables 3, 4). </sec><sec id="sec2_6"><title><text><SENT sid="15535" pm="."><plain>Genotypic Distributions and Allele Frequencies in Subjects with an Age of Onset of Less than 65 Years </plain></SENT>
</text></title><p><text><SENT sid="15536" pm="."><plain>Next, 163 cases with early-onset AD (EAD: n = 86) and age-matched NCs (n = 77) were compared; the age and sex ratios were not significantly different between the EAD and NC groups (table 3). </plain></SENT>
<SENT sid="15537" pm="."><plain>The genotype distributions of rs6332 (G/G: n = 51, G/A: n = 84, A/A: n = 27), rs6489630 (C/C: n = 94, C/T: n = 59, T/T: n = 8), and rs4930767 (T/T: n = 63, C/T: n = 74, C/C: n = 25) in the EAD group did not deviate significantly from the HWE (p &gt; 0.05) (table 4). </plain></SENT>
<SENT sid="15538" pm="."><plain>The results of power analyses demonstrated that the power ranged from 51.3% (rs6332) to 76.3% (rs4930767). </plain></SENT>
<SENT sid="15539" pm="."><plain>While the 3 genotypic distributions were not significantly deviated, significant differences in the allele frequencies of rs6332 and rs6489630 were observed between the EAD group and the age-matched NCs (former: χ2 = 4.687, d.f. = 1, p = 0.033, OR = 1.631; latter: χ2 = 4.605, d.f. = 1, p = 0.035, OR = 0.566) (table 4). </sec></sec></SecTag><SecTag type="DISCUSS"><sec sec-type="discussion" id="sec1_4"><title><text><SENT sid="15540" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="15541" pm="."><plain>In the present study, we found significant differences in the allele frequencies of the NTF-3 SNPs between patients with AD and the NCs and between the EAD group (&lt;65 years) and age-matched NCs (tables 2, 4). </plain></SENT>
<SENT sid="15542" pm="."><plain>While the A allele of rs6332 was associated with a risk of AD and EAD (former: OR = 1.602, 95% CI = 1.114-2.304; latter: OR = 1.631, 95% CI = 1.045-2.545), the T allele of rs6489630 was associated with a protective role only for EAD (OR = 0.566, 95% CI = 0.335-0.955). </plain></SENT>
<SENT sid="15543" pm="."><plain>We could not find a significant association between rs4930767 and the manifestation of AD (tables 1, 2, 3, 4). <p><text><SENT sid="15544" pm="."><plain>In previous studies, rs6332 was reported to be a robust candidate gene polymorphism for ADHD and to influence intelligence [27,29]. </plain></SENT>
<SENT sid="15545" pm="."><plain>We found that the executive function of G allele carriers was significantly lower than that of A allele carriers among AD patients. However, carrying the A allele was associated with a risk of EAD in the present study [20]. </plain></SENT>
<SENT sid="15547" pm="."><plain>The functional roles of rs6332 might influence executive dysfunction in comparatively older AD patients (approx. 74-76 years old) [20]. </plain></SENT>
<SENT sid="15549" pm="."><plain>On the other hand, rs6332 might be associated with the manifestation of AD in patients with EAD. <p><text><SENT sid="15550" pm="."><plain>Similarly, rs6489630 was reportedly associated with the intelligence of subjects with ADHD, and the intelligence scores of T allele carriers were significantly lower than those of C allele carriers [28]. </plain></SENT>
<SENT sid="15551" pm="."><plain>In contrast, the present results indicate a predominantly protective role associated with the T allele, compared with C allele carriers, with regard to the manifestation of EAD. Thus, functional SNPs of neurotrophins might have age-related reversible influences clinically between the young and the elderly, similar to the BDNF gene Val66Met polymorphism [33]. </plain></SENT>
<SENT sid="15553" pm="."><plain>Further investigations of age-dependent associations between the manifestation of AD and the NTF-3 gene are needed. <p><text><SENT sid="15554" pm="."><plain>A reduction in NTF-3 levels has been observed in septal regions containing neurotrophin-dependent cholinergic projections in APP mouse models [14]. </plain></SENT>
<SENT sid="15555" pm="."><plain>Furthermore, NTF-3 protects cortical neurons against Aβ-dependent neural cell death through the regulation of the phosphorylation pathway [17]. </plain></SENT>
<SENT sid="15556" pm="."><plain>The rs6332 SNP is a silent variation, and such synonymous polymorphisms have been implicated in the regulation of mRNA splicing or the translation of proteins [34]. </plain></SENT>
<SENT sid="15557" pm="."><plain>Therefore, rs6332 might influence synonymous polymorphisms that in turn might impact the regional translational level of NTF-3, leading to the regulation of cholinergic neuron projections. The rs6489630 SNP is located in an intron on the 3′-side, but its functional roles (e.g. transcriptional regulation of the NTF-3 gene) remain unclear and require further examination in the future. <p><text><SENT sid="15559" pm="."><plain>The present study has some limitations. First, the sample size in this study was comparatively small. Therefore, the statistical values were also small, and some type II errors may have occurred, possibly resulting in the failure to detect a significant association between rs4930767 and the risk of AD. To match the age (age range, 32-72 years) between the AD patients and NCs, we selected only 248 of the 507 participants. Moreover, we could not compare the relation between late-onset AD patients (&gt;65 years) and age-matched NCs because the sample size was too small (n = 85). </plain></SENT>
<SENT sid="15564" pm="."><plain>Regarding the statistical values, a previous study investigating the association between AD and the NTF-3 gene in the Japanese population reported the same p values (score range, 0.011-0.013) [23]. </plain></SENT>
<SENT sid="15565" pm="."><plain>Secondly, we could not confirm whether the significant differences in the allele frequencies between the patients with AD and the NCs had been influenced by neuroprotective actions against degenerative progression or neurodevelopmental factors. Thirdly, other representative SNPs in the Japanese population, such as the missense mutation Gly/-63/Glu, were not examined; however, the mutant type (-63 Glu) is too rare in Caucasian populations to be investigated in subsequent studies in other countries [23,26]. </plain></SENT>
<SENT sid="15567" pm="."><plain>Therefore, a larger sampling should be added to the present study, and the data should be re-evaluated in the future. <p><text><SENT sid="15568" pm="."><plain>In conclusion, despite some limitations, we found a significant association between AD and NTF-3 as well as between EAD and NTF-3. </plain></SENT>
<SENT sid="15569" pm="."><plain>These results may help to elucidate the neuroprotective or clinical age-related roles of not only the NTF-3 gene, but also other neurotrophin gene polymorphisms in neurodegenerative diseases described in previous studies [20,21,28,29,33]. </plain></SENT>
<SENT sid="15570" pm="."><plain>Furthermore, elucidating the detailed associations between NTF-3 gene diversity and the manifestation of AD itself will be an important task in the future. </sec></SecTag></body><back><SecTag type="REF"><ref-list><title>References</title><ref id="B1"><text><SENT sid="15571" pm="."><plain>1BaudicSBarbaGDThibaudetMCSmaggheARemyPTraykovLExecutive function deficit in early Alzheimer's disease and their relations with episodic memoryArch Clin Neuropsychol200621152116125364 </plain></SENT>
</text></ref><ref id="B2"><text><SENT sid="15572" pm="."><plain>2PerryRJWatsonPHodgeJRThe nature and staging of attention dysfunction in early (minimal and mild) Alzheimer's disease: relationship to episodic and semantic memory impairmentNeuropsychologia20003825227110678692 </plain></SENT>
</text></ref><ref id="B3"><text><SENT sid="15573" pm="."><plain>3PetersenRCDoodyRKurzACurrent concepts in mild cognitive impairmentArch Neurol2001581985199211735772 </plain></SENT>
</text></ref><ref id="B4"><text><SENT sid="15574" pm="."><plain>4HardyJAllsopDAmyloid deposition as the central event in the aetiology of Alzheimer's diseaseTrends Pharmacol Sci1991123833881763432 </plain></SENT>
</text></ref><ref id="B5"><text><SENT sid="15575" pm="."><plain>5BraakHBraakENeuropathological stageing of Alzheimer-related changesActa Neuropathol1991822392591759558 </plain></SENT>
</text></ref><ref id="B6"><text><SENT sid="15576" pm="."><plain>6CorderEHSaundersAMStrittmatterWJSchmechelDEGaskellPCSmallGWRosesADHainesJLPericak-VanceMAGene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset familiesScience19932619219238346443 </plain></SENT>
</text></ref><ref id="B7"><text><SENT sid="15577" pm="."><plain>7HaroldDAbrahamRHollingworthPSimsRGerrishAHamshereMLPahwaJSMoskvinaVGenome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's diseaseNat Genet2009411088109319734902 </plain></SENT>
</text></ref><ref id="B8"><text><SENT sid="15578" pm="."><plain>8OharaTNinomiyaTHirakawaYAshikawaKMonjiAKiyoharaYKanbaSKuboMAssociation study of susceptibility genes for late-onset Alzheimer's disease in the Japanese populationPsychiatr Genet20122229029322935915 </plain></SENT>
</text></ref><ref id="B9"><text><SENT sid="15579" pm="."><plain>9BettensKSleegersKVan BroeckhovenCCurrent status on Alzheimer disease molecular genetics: from past, to present, to futureHum Mol Genet201019R1R4R1120388643 </plain></SENT>
</text></ref><ref id="B10"><text><SENT sid="15580" pm="."><plain>10OharaTDoiYNinomiyaTHirakawaYHataJIwakiTKanbaSKiyoharaYGlucose tolerance status and risk of dementia in the community: the Hisayama studyNeurology2011771126113421931106 </plain></SENT>
</text></ref><ref id="B11"><text><SENT sid="15581" pm="."><plain>11HockCHeeseKHuletteCRosenbergCOttenURegion-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areasArch Neurol20005784685110867782 </plain></SENT>
</text></ref><ref id="B12"><text><SENT sid="15582" pm="."><plain>12DuranyNMichelTKurtJCruz-SánchezFFCervós-NavarroJRiedererPBrain-derived neurotrophic factor and neurotrophin-3 levels in Alzheimer's disease brainsInt J Dev Neurosci200018807813 </plain></SENT>
</text></ref><ref id="B13"><text><SENT sid="15583" pm="."><plain>13Narisawa-SaitoMWakabayashiKTsujiSTakahashiHNawaHRegional specificity of alterations in NGF, BDNF and NTF-3 levels in Alzheimer's diseaseNeuroreport19967292529289116211 </plain></SENT>
</text></ref><ref id="B14"><text><SENT sid="15584" pm="."><plain>14Schulte-HerbrüggenOEckartSDeickeUKühlAOttenUDanker-HopfeHAbramowskiDStaufenbielMHellwegRAge-dependent time course of cerebral brain-derived neurotrophic factor, nerve growth factor, and neurotrophin-3 in APP23 transgenic miceJ Neurosci Res2008862774278318438945 </plain></SENT>
</text></ref><ref id="B15"><text><SENT sid="15585" pm="."><plain>15NagaharaAHMerrillDACoppolaGTsukadaSSchroederBEShakedGMWangLBleschAKimAConnerJMRockensteinEChaoMVKooEHGeschwindDMasliahEChibaAATuszynskiMHNeuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's diseaseNat Med20091533133719198615 </plain></SENT>
</text></ref><ref id="B16"><text><SENT sid="15586" pm="."><plain>16TuszynskiMHThalLPayMSalmonDPUHSBakayRPatelPBleschAVahlsingHLHoGTongGPotkinSGFallonJHansenLMufsonEJKordowerJHGallCConnerJA phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer diseaseNat Med20051155155515852017 </plain></SENT>
</text></ref><ref id="B17"><text><SENT sid="15587" pm="."><plain>17LesnéSGabrielCNelsonDAWhiteEMackenzieETVivienDBuissonAAkt-dependent expression of NAIP-1 protects neurons against amyloid-β toxicityJ Biol Chem2005280249412494715797869 </plain></SENT>
</text></ref><ref id="B18"><text><SENT sid="15588" pm="."><plain>18ManessLMKastinAJWeberJTBanksWABeckmanBSZadinaJEThe neurotrophins and their receptors: structure, function, and neuropathologyNeurosci Biobehav Rev1994181431598170621 </plain></SENT>
</text></ref><ref id="B19"><text><SENT sid="15589" pm="."><plain>19MaisonpierrePCLe BeauMMEspinosaR3rdIpNYBelluscioLde la MonteSMSquintoSFurthMEYancopoulosGDHuman and rat brain-derived neurotrophic factor and neurotrophin-3: gene structures, distributions, and chromosomal localizationsGenomics1991105585681889806 </plain></SENT>
</text></ref><ref id="B20"><text><SENT sid="15590" pm="."><plain>20KobayashiNNagataTShinagawaSNakayamaRKondoKNakayamaKYamadaHAssociation between neurotrophin-3 polymorphisms and executive function in Japanese patients with amnestic mild cognitive impairment and mild Alzheimer diseaseDement Geriatr Cogn Disord20123419019723075484 </plain></SENT>
</text></ref><ref id="B21"><text><SENT sid="15591" pm="."><plain>21NagataTShinagawaSNukariyaKYamadaHNakayamaKAssociation between BDNF polymorphism (Val66Met) and executive function in patients with amnestic mild cognitive impairment or mild Alzheimer diseaseDement Geriatr Cogn Disord20123326627222699449 </plain></SENT>
</text></ref><ref id="B22"><text><SENT sid="15592" pm="."><plain>22AkatsuHYamagataHDKawamataJKaminoKTakedaMYamamotoTMikiTTooyamaIShimohamaSKosakaKVariations in the BDNF gene in autopsy-confirmed Alzheimer's disease and dementia with Lewy bodies in JapanDement Geriatr Cogn Disord20062221622216899999 </plain></SENT>
</text></ref><ref id="B23"><text><SENT sid="15593" pm="."><plain>23KunugiHHattoriMUekiAIsseKHirasawaHNankoSPossible association of missense mutation (Gly[-63]Glu) of the neurotrophin-3 gene with Alzheimer's disease in JapaneseNeurosci Lett199824165679502217 </plain></SENT>
</text></ref><ref id="B24"><text><SENT sid="15594" pm="."><plain>24KunugiHUekiAOtsukaMIsseKHirasawaHKatoNNabikaTKobayashiSNankoSA novel polymorphism of the brain-derived neurotrophic factor (BDNF) gene associated with late-onset Alzheimer's diseaseMol Psychiatry20016838611244490 </plain></SENT>
</text></ref><ref id="B25"><text><SENT sid="15595" pm="."><plain>25NagataTShinagawaSNukariyaKNakayamaRNakayamaKYamadaHAssociation between nerve growth factor gene polymorphism and executive dysfunction in Japanese patients with early-stage Alzheimer's disease and amnestic mild cognitive impairmentDement Geriatr Cogn Disord20113237938622301435 </plain></SENT>
</text></ref><ref id="B26"><text><SENT sid="15596" pm="."><plain>26JŏnssonEBrenéSZhangXRNimgaonkarVLTylecASchallingMSedvallGSchizophrenia and neurotrophin-3 allelesActa Psychiatr Scand1997954144199197906 </plain></SENT>
</text></ref><ref id="B27"><text><SENT sid="15597" pm="."><plain>27RibasésMHervásARamos-QuirogaJABoschRBielsaAGastaminzaXFernández-AnguianoMNogueiraMGómez-BarrosNValeroSGratacòsMEstivillXCasasMCormandBBayésMAssociation study of 10 genes encoding neurotrophic factors and their receptors in adult and child attention-deficit/hyperactivity disorderBiol Psychiatry20086393594518179783 </plain></SENT>
</text></ref><ref id="B28"><text><SENT sid="15598" pm="."><plain>28ChoSCKimHWKimBNKimJWShinMSChoDYChungSJungSWYooHJChungIWChungUSSonJWNeurotrophin-3 gene, intelligence, and selective attention deficit in a Korean sample with attention-deficit/hyperactivity disorderProg Neuropsychopharmacol Biol Psychiatry2010341065106920576502 </plain></SENT>
</text></ref><ref id="B29"><text><SENT sid="15599" pm="."><plain>29ConnerACKisslingCHodgesEHünnerkopfRClementRMDudleyEFreitagCMRöslerMRetzWThomeJNeurotrophic factor-related gene polymorphisms and adult attention deficit hyperactivity disorder (ADHD) score in a high-risk male populationAm J Med Genet B Neuropsychiatr Genet2008147B1476148018428117 </plain></SENT>
</text></ref><ref id="B30"><text><SENT sid="15600" pm="."><plain>30McKhannGDrachmanDFolsteinMKatzmanRPriceDStadlanEMClinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's DiseaseNeurology1984349399446610841 </plain></SENT>
</text></ref><ref id="B31"><text><SENT sid="15601" pm="."><plain>31PetersenRCDoodyRKurzACurrent concepts in mild cognitive impairmentArch Neurol2001581985199211735772 </plain></SENT>
</text></ref><ref id="B32"><text><SENT sid="15602" pm="."><plain>32HuangRHuangJCathcartHSmithSPodusloSEGenetic variants in brain-derived neurotrophic factor associated with Alzheimer's diseaseJ Med Genet200744e6617293537 </plain></SENT>
</text></ref><ref id="B33"><text><SENT sid="15603" pm="."><plain>33VoineskosANLerchJPFelskyDShaikhSRajjiTKMirandaDLobaughNJMulsantBHPollockBGKennedyJLThe brain-derived neurotrophic factor Val66Met polymorphism and prediction of neural risk for Alzheimer diseaseArch Gen Psychiatry20116819820621300947 </plain></SENT>
</text></ref><ref id="B34"><text><SENT sid="15604" pm="."><plain>34Kimchi-SarfatyCOhJMKimIWSaunaZECalcagnoAMAmbudkarSVGottesmanMMA ‘silent’ polymorphism in the MDR1 gene changes substrate specificityScience200731552552817185560 </plain></SENT>
</text></ref></ref-list></SecTag></back><floats-group><SecTag type="TABLE"><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p><text><SENT sid="15605" pm="."><plain>Total subject characteristics (n = 248) </caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"><text><SENT sid="15606" pm="."><plain>Total AD (n = 143) </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="15607" pm="."><plain>NC (n = 105) </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="15608" pm="."><plain>χ2 or F score </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="15609" pm="."><plain>p value </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15610" pm="."><plain>Age, years </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="15611" pm="."><plain>61.92 ± 7.10 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="15612" pm="."><plain>60.21 ± 7.35 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="15613" pm="."><plain>3.426 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="15614" pm="."><plain>0.065 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15615" pm="."><plain>Sex ratio (M/F) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="15616" pm="."><plain>67/76 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="15617" pm="."><plain>44/61 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="15618" pm="."><plain>0.600a </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="15619" pm="."><plain>0.518 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn><p>Values represent number of patients or means ± SD.</p></fn><fn id="T1F1"><label>a</label><p>The χ<sup>2</sup> score. One-way ANOVA with post hoc tests (Tukey) for age: AD versus NC.</p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><p><text><SENT sid="15620" pm="."><plain>Association between NTF-3 and total AD patients </caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"><text><SENT sid="15621" pm="."><plain>AD (n = 141)1 </plain></SENT>
</text></th><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"><text><SENT sid="15622" pm="."><plain>NC (n = 105) </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15623" pm="."><plain>rs6332 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15624" pm="."><plain>Genotype frequency </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15625" pm="."><plain>G/G </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="15626" pm="."><plain>33 (23.4%) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15627" pm="."><plain>38 (36.2%) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15628" pm="."><plain>G/A </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="15629" pm="."><plain>76 (53.9%) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15630" pm="."><plain>54 (51.4%) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15631" pm="."><plain>A/A </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="15632" pm="."><plain>32 (22.7%) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15633" pm="."><plain>13 (12.4%) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15634" pm="."><plain>χ2 score </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15635" pm="."><plain>6.979 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15636" pm="."><plain>p value </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15637" pm="."><plain>0.031* </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1"><text><SENT sid="15638" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15639" pm="."><plain>Allele frequency </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15640" pm="."><plain>G </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="15641" pm="."><plain>142 (50.4%) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15642" pm="."><plain>130 (61.9%) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15643" pm="."><plain>A </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="15644" pm="."><plain>140 (49.6%) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15645" pm="."><plain>80 (38.1%) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15646" pm="."><plain>χ2 score </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15647" pm="."><plain>6.496 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15648" pm="."><plain>p value </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15649" pm="."><plain>0.013* </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15650" pm="."><plain>OR (95% CI) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15651" pm="."><plain>1.602 (1.114–2.304) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1"><text><SENT sid="15652" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15653" pm="."><plain>rs6489630 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15654" pm="."><plain>Genotype frequency </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15655" pm="."><plain>C/C </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="15656" pm="."><plain>87 (62.1%) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15657" pm="."><plain>54 (51.4%) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15658" pm="."><plain>C/T </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="15659" pm="."><plain>49 (35.0%) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15660" pm="."><plain>44 (41.9%) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15661" pm="."><plain>T/T </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="15662" pm="."><plain>4 (2.9%) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15663" pm="."><plain>7 (6.7%) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15664" pm="."><plain>χ2 score </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15665" pm="."><plain>3.89 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15666" pm="."><plain>p value </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15667" pm="."><plain>0.143 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1"><text><SENT sid="15668" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15669" pm="."><plain>Allele frequency </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15670" pm="."><plain>C </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="15671" pm="."><plain>223 (79.6%) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15672" pm="."><plain>152 (72.4%) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15673" pm="."><plain>T </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="15674" pm="."><plain>57 (20.4%) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15675" pm="."><plain>58 (27.6%) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15676" pm="."><plain>χ2 score </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15677" pm="."><plain>3.523 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15678" pm="."><plain>p value </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15679" pm="."><plain>0.067 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15680" pm="."><plain>OR (95% CI) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15681" pm="."><plain>0.670 (0.440–1.019) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1"><text><SENT sid="15682" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15683" pm="."><plain>rs4930767 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15684" pm="."><plain>Genotype frequency </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15685" pm="."><plain>T/T </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="15686" pm="."><plain>51 (36.2%) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15687" pm="."><plain>43 (41.0%) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15688" pm="."><plain>C/T </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="15689" pm="."><plain>68 (48.2%) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15690" pm="."><plain>44 (41.9%) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15691" pm="."><plain>C/C </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="15692" pm="."><plain>22 (15.6%) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15693" pm="."><plain>18 (17.1%) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15694" pm="."><plain>χ2 score </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15695" pm="."><plain>0.976 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15696" pm="."><plain>p value </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15697" pm="."><plain>0.614 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1"><text><SENT sid="15698" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15699" pm="."><plain>Allele frequency </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15700" pm="."><plain>T </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="15701" pm="."><plain>170 (60.3%) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15702" pm="."><plain>130 (61.9%) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15703" pm="."><plain>C </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="15704" pm="."><plain>112 (39.7%) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15705" pm="."><plain>80 (38.1%) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15706" pm="."><plain>χ2 score </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15707" pm="."><plain>0.133 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15708" pm="."><plain>p value </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15709" pm="."><plain>0.779 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15710" pm="."><plain>OR (95% CI) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15711" pm="."><plain>1.071 (0.742–1.545) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="T2F1"><label>*</label><p>p &lt; 0.05.</p></fn><fn id="T2F2"><label>1</label><p>For rs6489630, there were only 140 AD patients.</p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><p><text><SENT sid="15712" pm="."><plain>Characteristics of subjects aged &lt;65 years (n = 163) </caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"><text><SENT sid="15713" pm="."><plain>AD (n = 86) </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="15714" pm="."><plain>NC (n = 77) </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="15715" pm="."><plain>χ2 or F score </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="15716" pm="."><plain>p value </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15717" pm="."><plain>Age, years </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="15718" pm="."><plain>57.38 ± 5.28 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="15719" pm="."><plain>57.23 ± 6.21 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="15720" pm="."><plain>0.028 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="15721" pm="."><plain>0.868 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15722" pm="."><plain>Sex ratio (M/F) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="15723" pm="."><plain>43/43 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="15724" pm="."><plain>36/41 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="15725" pm="."><plain>0.171* </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="15726" pm="."><plain>0.754 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn><p>Values represent number of patients or means ± SD.</p></fn><fn id="T3F1"><label>a</label><p>The χ<sup>2</sup> score. One-way ANOVA with post hoc tests (Tukey) for age: AD versus NC.</p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4</label><caption><p><text><SENT sid="15727" pm="."><plain>Association between NTF-3 and EAD patients aged &lt;65 years </caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"><text><SENT sid="15728" pm="."><plain>AD (n = 85)1 </plain></SENT>
</text></th><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"><text><SENT sid="15729" pm="."><plain>NC (n = 77) </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15730" pm="."><plain>rs6332 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15731" pm="."><plain>Genotype frequency </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15732" pm="."><plain>G/G </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="15733" pm="."><plain>21 (24.7%) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15734" pm="."><plain>30 (39.0%) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15735" pm="."><plain>G/A </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="15736" pm="."><plain>46 (54.1%) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15737" pm="."><plain>38 (49.3%) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15738" pm="."><plain>A/A </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="15739" pm="."><plain>18 (21.2%) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15740" pm="."><plain>9 (11.7%) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15741" pm="."><plain>χ2 score </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15742" pm="."><plain>4.967 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15743" pm="."><plain>p value </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15744" pm="."><plain>0.083 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1"><text><SENT sid="15745" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15746" pm="."><plain>Allele frequency </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15747" pm="."><plain>G </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="15748" pm="."><plain>88 (51.8%) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15749" pm="."><plain>98 (63.6%) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15750" pm="."><plain>A </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="15751" pm="."><plain>82 (48.2%) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15752" pm="."><plain>56 (36.4%) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15753" pm="."><plain>χ2 score </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15754" pm="."><plain>4.687 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15755" pm="."><plain>p value </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15756" pm="."><plain>0.033* </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15757" pm="."><plain>OR (95% CI) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15758" pm="."><plain>1.631 (1.045–2.545) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1"><text><SENT sid="15759" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15760" pm="."><plain>rs6489630 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15761" pm="."><plain>Genotype frequency </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15762" pm="."><plain>C/C </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="15763" pm="."><plain>56 (66.7%) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15764" pm="."><plain>38 (49.4%) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15765" pm="."><plain>C/T </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="15766" pm="."><plain>25 (29.8%) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15767" pm="."><plain>34 (44.2%) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15768" pm="."><plain>T/T </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="15769" pm="."><plain>3 (3.5%) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15770" pm="."><plain>5 (6.4%) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15771" pm="."><plain>χ2 score </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15772" pm="."><plain>5.025 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15773" pm="."><plain>p value </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15774" pm="."><plain>0.081 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1"><text><SENT sid="15775" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15776" pm="."><plain>Allele frequency </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15777" pm="."><plain>C </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="15778" pm="."><plain>137 (81.5%) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15779" pm="."><plain>110 (71.4%) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15780" pm="."><plain>T </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="15781" pm="."><plain>31 (18.5%) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15782" pm="."><plain>44 (28.6%) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15783" pm="."><plain>χ2 score </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15784" pm="."><plain>4.605 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15785" pm="."><plain>p value </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15786" pm="."><plain>0.035* </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15787" pm="."><plain>OR (95% CI) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15788" pm="."><plain>0.566 (0.335–0.955) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1"><text><SENT sid="15789" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15790" pm="."><plain>rs4930767 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15791" pm="."><plain>Genotype frequency </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15792" pm="."><plain>T/T </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="15793" pm="."><plain>31 (36.5%) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15794" pm="."><plain>32 (41.6%) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15795" pm="."><plain>C/T </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="15796" pm="."><plain>41 (48.2%) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15797" pm="."><plain>33 (42.9%) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15798" pm="."><plain>C/C </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="15799" pm="."><plain>13 (15.3%) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15800" pm="."><plain>12 (15.6%) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15801" pm="."><plain>χ2 score </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15802" pm="."><plain>0.527 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15803" pm="."><plain>p value </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15804" pm="."><plain>0.768 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1"><text><SENT sid="15805" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15806" pm="."><plain>Allele frequency </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15807" pm="."><plain>T </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="15808" pm="."><plain>103 (60.6%) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15809" pm="."><plain>97 (63%) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15810" pm="."><plain>C </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="15811" pm="."><plain>67 (39.4%) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15812" pm="."><plain>57 (37%) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15813" pm="."><plain>χ2 score </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15814" pm="."><plain>0.197 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15815" pm="."><plain>p value </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15816" pm="."><plain>0.731 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="15817" pm="."><plain>OR (95% CI) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="15818" pm="."><plain>1.107 (0.707–1.734) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p>* p &lt; 0.05.</p></fn><fn id="T4F1"><label>1</label><p>For rs6489630, the re were only 84 AD patients.</p></fn></table-wrap-foot></table-wrap></SecTag></floats-group></article>
